Ignite Creation Date:
2025-12-24 @ 2:16 PM
Ignite Modification Date:
2025-12-25 @ 2:54 PM
Study NCT ID:
NCT00057395
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2003-04-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Sponsor:
Aronex Pharmaceuticals
Organization:
Study Overview
Official Title:
A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies
Status:
UNKNOWN
Status Verified Date:
2004-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
Detailed Description:
Primary Objective:
* Determine response rate (RR; complete and partial response \[CR, PR\]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies.
Secondary Objective:
* Determine the safety and tolerability of Aroplatin
* Determine response rate (RR; complete and partial response \[CR, PR\]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies.
Secondary Objective:
* Determine the safety and tolerability of Aroplatin
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: